Cancer specialists who recommended breast cancer recurrence test such as CanAssist Breast to patients have faced several such inhibitions from them. Here are a few more challenges that cancer specialists face while educating the patients about
breast cancer recurrence tests:
Most of the cancer recurrence tests are expensive and comes as a huge burden to the patients. It adds to the existing diagnosis, medication, surgery, and other treatment-related bills.
However, patients should look at it as an expense that could save them from heavier medical expenses, especially from chemotherapy and radiation. Patients whose breast cancer recurrence score is low can skip chemotherapy, thereby can save lakhs of rupees. Also, the cancer care specialists will have better knowledge about the tumor and can accordingly personalize the treatment, thereby; avoiding overtreatment and undertreatment.
Trust-worthiness of machine-based tests :
In India, companies are using AI and machine learning-based tests for better cancer diagnosis and treatment by making it accurate, accessible, and affordable. Among the most significant advantages of using AI and machine learning is that these technologies can read a large amount of data with accuracy and within less time.
CanAssist Breast digitizes historical medical records of patients, feeds into an AI-algorithm which then analyzes the reports to create actionable insights for doctors. The test reads and analyzes tissue abnormality and identifies tumors that can develop into cancer – a benefit of technology that human expertise cannot possibly match.
Future predictability :
Some breast cancers are driven by natural hormones, estrogen, and progesterone. Clinicians refer to these cancers as hormone receptor-positive if they are estrogen receptor-positive (ER positive) and/or progesterone receptor-positive (PR positive). Hormone therapy for breast cancer is only used to treat cancers that are ER or PR positive.
Despite conventional hormone therapy, approximately 20–30% of patients with hormone receptor-positive breast cancer will suffer recurrences and the development of metastatic disease.
Considerable progress has been made in this area, and newer therapeutic targets have been developed against several hormonal resistance mechanisms. Experts at OncoStem perform the test by analyzing the expression of five protein biomarkers using OncoStem’s proprietary machine-learning algorithm. The test reprt is dispatched within ten business days. The doctor and patient can further discuss the test reports and personalize the treatment.
Want to know more about our breast cancer recurrence test? Get in touch with us!